North America’s medical devices industry saw a drop of 38.60% in deal activity during November 2022, when compared with the last 12-month average, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 70 medical devices industry deals worth $28.9bn were announced for the region in November 2022, against the 12-month average of 114 deals.
Of all the deal types, venture financing saw most activity in November 2022 with 35 transactions, representing a 50% share for the region.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In second place was M&A with 31 deals, followed by private equity deals with four transactions, respectively capturing a 44.3% and 5.7% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $28.21bn, while private equity and venture financing deals totalled $467.67m and $231.31m, respectively.
North America medical devices industry deals in November 2022: Top deals
The top five medical devices deals accounted for 98.8% of the overall value during November 2022.
The combined value of the top five medical devices deals stood at $28.56bn, against the overall value of $28.9bn recorded for the month.
The top five medical devices industry deals of November 2022 tracked by GlobalData were:
1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed
2) The $8.9bn acquisition of Summit Health by VillageMD
3) WerfenLife’s $2bn acquisition deal with Immucor
4) The $615m acquisition of Apollo Endosurgery by Boston Scientific
5) Arsenal Capital Partners’s $449m private equity deal for 18% stake in Certara